Socio-Demographic Profile and Prevalence of Tuberculosis (TB) Treatment Outcomes among Tuberculosis/Human Immunodeficiency Virus (TB/HIV) Co-Infected Patients in Kelantan

被引:0
|
作者
Nor, Siti Romaino Mohd [1 ,2 ]
Husin, Mohd Rozi [3 ]
Jaeb, Mat Zuki Mat [4 ]
Naing, Nyi Nyi [1 ]
机构
[1] Univ Sultan Zainal Abidin, Fac Med, Med Campus,Jalan Sultan Mahmud, Kuala Terengganu 20400, Terengganu, Malaysia
[2] Hosp Raja Perempuan Zainab II, Clin Res Ctr Kelantan, Kota Baharu 15586, Kelantan, Malaysia
[3] Jabatan Kesihatan Negeri Kelantan, TB Leprosy Sect, Kota Baharu 15200, Kelantan, Malaysia
[4] Hosp Raja Perempuan Zainab II, Dept Med, Resp Unit, Kota Baharu 15586, Kelantan, Malaysia
来源
PERTANIKA JOURNAL OF SCIENCE AND TECHNOLOGY | 2021年 / 29卷 / 04期
关键词
Co-infected patients; Human Immunodeficiency Virus; HIV; prevalence; socio-demographic; Tuberculosis; TB; PREDICTORS;
D O I
10.47836/pjst.29.4.03
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
In Kelantan, the prevalence of Tuberculosis (TB) treatment success rate among TB/HIV co-infection is still below the success target of the World Health Organisation (WHO). Our objective was to assess the socio-demographic profile and determine the prevalence of TB treatment outcomes among TB/HIV co-infected patients in Kelantan. The crosssectional study involved secondary data from the MyTB online system from January 2014 to December 2018, carried out at TB/Leprosy Sector, State Health Department of Kelantan. The data were analysed using SPSS version 25.0 and STATA version 14. The ethics approval was obtained from the UniSZA Human Research Ethics Committee (UHREC) and Medical Research Ethics Committee (MREC) of Ministry of Health (MOH). There were 6,313 TB cases in Kelantan. Of these, 703 (11.1%) cases were TB/HIV co-infection. However, 36 cases were excluded, and 667 cases were evaluated based on inclusion and exclusion criteria. The mean (SD) age was 38.7 (7.9) years, and the mean duration of TB treatment was 202.8 (131.27) days. The prevalence of successful treatment was 57.1%, with 19.8% cases were cured, and another 37.3% cases were completed treatment. While the unsuccessful were 42.9%, with 10.1% cases were defaulted, and 32.8% cases died. The successful outcomes were significantly associated with the educational level, the anatomy of TB location, smoking status, DOTS by health care providers, source of notification, the place of treatment and method of detection. This study provides the basic data of patient's socio-demographic profiles, and the prevalence of TB treatment success in Kelantan is under international target by WHO of >= 90.0%.
引用
收藏
页码:2279 / 2293
页数:15
相关论文
共 50 条
  • [41] Feasibility and acceptability of antimycolic acid antibodies in the diagnosis of pulmonary tuberculosis in TB/HIV co-infected patients
    Elhassan, O. A.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2012, 17 : 34 - 34
  • [42] The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis
    Gengiah, Tanuja N.
    Holford, Nicholas H. G.
    Botha, Julia H.
    Gray, Andrew L.
    Naidoo, Kogieleum
    Karim, Salim S. Abdool
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (05) : 689 - 695
  • [43] The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis
    Tanuja N. Gengiah
    Nicholas H. G. Holford
    Julia H. Botha
    Andrew L. Gray
    Kogieleum Naidoo
    Salim S. Abdool Karim
    European Journal of Clinical Pharmacology, 2012, 68 : 689 - 695
  • [44] CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS ASSOCIATED WITH UNFAVOURABLE TUBERCULOSIS TREATMENT OUTCOMES IN TB-HIV CO-INFECTED PATIENTS IN BRAZIL: A HIERARCHICAL POLYTOMOUS ANALYSIS
    Prado, T. N.
    Rajan, J. V.
    Miranda, A. E.
    Dias, E. S.
    Cosme, L. B.
    Possuelo, L. G.
    Sanchez, M. N.
    Maciel, E. L.
    SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A220 - A220
  • [45] Humoral immune responses to multiple antigens of Mycobacterium tuberculosis in tuberculosis patients co-infected with the human immunodeficiency virus
    Colangeli, R
    Antinori, A
    Cingolani, A
    Ortona, L
    Lyashchenko, K
    Fadda, G
    Gennaro, ML
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 1999, 3 (12) : 1127 - 1131
  • [46] Clinical and epidemiological characteristics associated with unfavorable tuberculosis treatment outcomes in TB-HIV co-infected patients in Brazil: a hierarchical polytomous analysis
    do Prado, Thiago Nascimento
    Rajan, Jayant V.
    Miranda, Angelica Espinosa
    Dias, Elias dos Santos
    Cosme, Lorrayne Beliqui
    Possuelo, Lia Goncalves
    Sanchez, Mauro N.
    Golub, Jonathan E.
    Riley, Lee W.
    Maciel, Ethel Leonor
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2017, 21 (02): : 162 - 170
  • [47] Prognostic score to predict mortality during TB treatment in TB/HIV co-infected patients
    Nguyen, Duc T.
    Jenkins, Helen E.
    Graviss, Edward A.
    PLOS ONE, 2018, 13 (04):
  • [48] Proportion of Multidrug-Resistant Tuberculosis in Human Immunodeficiency Virus/Mycobacterium tuberculosis Co-Infected Patients in Korea
    Joh, Joon Sung
    Hong, H. Christian
    Jeong, In A.
    Chin, Bum Sik
    Yang, Hye Jin
    Choi, Hongjo
    Bang, Ji Hwan
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (10) : 1143 - 1146
  • [49] Prognostic Score to Predict Mortality During TB Treatment in TB/HIV Co-Infected Patients
    Nguyen, D. T.
    Jenkins, H. E.
    Graviss, E. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [50] Hepatic Safety of High-Dose Rifampicin for Tuberculosis Treatment in TB/HIV Co-infected Patients: A Randomized Clinical Trial
    Sanni, Sekossounon
    Wachinou, Ablo Prudence
    Merle, Corinne Simone Colette
    Bekou, Kossi Wilfried
    Esse, Marius
    Gossa, Severin
    Gomina, Khalil
    Baba-Moussa, Lamine
    Affolabi, Dissou
    ARCHIVES OF PHARMACY PRACTICE, 2021, 12 (03) : 66 - 72